Strategic research on drug combination products 2024:

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) — The report “Drug Device Combination Products – Global Strategic Business Report” has been updated ResearchAndMarkets.com Offer.

The global drug combination products market was valued at $114.8 billion in 2023 and is expected to reach $158.7 billion by 2030, growing at a CAGR of 4.7% from 2023 to 2030. This comprehensive report provides in-depth market analysis trends, drivers and forecasts to help you make informed business decisions.

The growth of the drug combination products market is driven by several factors, including technological advancements, favorable regulatory environment, and increasing prevalence of chronic diseases. A key driver is the increasing demand for minimally invasive treatments that offer better patient compliance and better outcomes. The increasing adoption of digital health technologies and intelligent drug delivery systems is also increasing the effectiveness and convenience of combination products, making them more attractive to both healthcare providers and patients.

In addition, the expansion of healthcare infrastructure in emerging markets and the increasing focus on personalized medicine support the development and launch of these products. Strategic collaborations between pharmaceutical companies, medical device manufacturers and research institutions continue to drive innovation and market growth. These factors, coupled with continuous advancement in materials science and drug formulation technologies, are driving the global drug-device combination products market.

What are drug combination products and why are they important?

Drug-device combination products are innovative therapeutic solutions that combine drugs, devices and sometimes biologics to improve the effectiveness, safety and convenience of treating various diseases. These products are becoming increasingly important in the healthcare industry as they provide better treatment outcomes through synergistic effects and enable targeted drug delivery, controlled release and reduced side effects.

Common examples include drug-eluting stents, prefilled syringes, inhalers, transdermal patches, and drug-coated implantable devices. Drug and device integration is particularly valuable in chronic disease management, oncology and cardiovascular treatments, where precision, control and patient compliance are critical. As demand for personalized and effective treatment options grows, drug and device combination products are becoming an essential part of modern healthcare.

How are technological advancements driving the drug-device combination products market?

Technological advancements are significantly driving the growth and development of the drug-device combination products market. Innovations in drug delivery systems, such as microneedle patches, smart inhalers and bioabsorbable stents, are improving patient compliance and therapeutic efficacy. Integration of digital health technologies, including sensors and wireless connectivity, enables real-time monitoring of patient compliance and medication administration, providing healthcare providers with valuable data to optimize treatment plans.

In addition, the development of novel materials such as biocompatible polymers and hydrogels improves the safety and effectiveness of implantable devices and reduces the risk of side effects. The use of 3D printing technology in the manufacture of combination products also enables greater customization and precision to address the specific needs of individual patients. These technological advances are changing the market landscape by offering innovative solutions that address unmet clinical needs.

What influence do regulatory pathways and market dynamics have on drug combination products?

The regulatory landscape for drug-device combination products is complex, as these products must meet the standards of both drug and device regulations. Regulatory authorities such as the FDA and EMA are increasingly developing specific guidelines to streamline the approval process for combination products, ensuring safety and effectiveness while reducing time to market. This regulatory framework encourages innovation by providing clearer pathways for the development and marketing of combination products.

Market dynamics such as increasing prevalence of chronic diseases, aging population, and demand for minimally invasive treatments continue to drive the adoption of drug-device combination products. The increasing focus on patient-centered care and the need for cost-effective healthcare solutions are also driving the use of these products as they enable better treatment outcomes and shorter hospital stays.

Key Takeaways:

• Market Growth: Understand the significant growth trajectory of the Transdermal Patches segment, which is expected to reach $53.4 billion by 2030, at a compound annual growth rate of 4.5%. The inhalers segment is also expected to grow at a CAGR of 5.8% during the analysis period.
• Regional Analysis: Get insights into the US market, valued at $30.6 billion in 2023, and China, which is expected to grow at an impressive 8.3% annually to $36.2 billion by 2030. Dollar is forecast. Discover growth trends in other key regions including Japan and Canada, Germany and Asia Pacific.

Reporting features:

• Comprehensive market data: Independent analysis of annual sales and market forecasts in millions of US dollars from 2023 to 2030.
• Detailed Regional Analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, Latin America, the Middle East and Africa.
• Company Profiles: Coverage of key players such as Abbott Laboratories, Alcon, a Novartis company, Allergan PLC and more.
• Free Updates: Receive one year of free report updates to keep you up to date on the latest market developments.

Why you should buy this report:

• Detailed Market Analysis: Access a comprehensive analysis of the global drug device combination products market, covering all major geographical regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of key players in different regions.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the global drug device combination products market.
• Actionable insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key questions answered:

• How is the global drug combination products market expected to develop by 2030?
• What are the key drivers and restraints affecting the market?
• Which market segments will grow the most during the forecast period?
• How will the market shares of different regions and segments change by 2030?
• Who are the leading players in the market and what are their prospects?

Key attributes:

Main topics covered:

MARKET OVERVIEW

• Insights into the influencer market
• World market trends
• Impact of COVID-19 and a looming global recession
• Drug combination products – percentage market share of major global competitors in 2024 (E)
• Competitive market presence – strong/active/niche/trivial for players worldwide in 2024 (E)

Market trends and drivers

• Increasing demand for minimally invasive treatment solutions
• Increasing acceptance of drug-eluting stents and implantable devices
• Technological advances in drug delivery mechanisms for improved efficacy
• Growing focus on patient-centered and personalized healthcare solutions
• Expanding the possible applications of combination products in the treatment of chronic diseases
• Impact of Regulatory Approvals and Fast Track Designations on Market Growth
• Increasing collaboration between pharmaceutical and medical device companies
• Development of intelligent drug-device combinations with digital health integration
• Increasing demand for biodegradable and implantable drug delivery systems
• Impact of the aging population and the growing burden of chronic diseases
• Increasing investments in research and development for novel combination products
• New opportunities in emerging markets for drug-device combinations

Focus on selected players (46 featured in total)

• Abbott Laboratories
• Alcon, a Novartis company
• Allergan PLC
• Arrow International, Inc.
• Bausch & Lomb, Inc.
• Boston Scientific Corporation
• CR Bard, Inc.
• CareFusion Corporation
• Ethicon US LLC
• Medline Industries, Inc.
• Medtronic PLC
• Mylan NV
• Stryker Corporation
• Terumo Corporation
• WL Gore & Associates, Inc.

For more information about this report, see

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• Drug Device Combination Products Market